Welcome to visit Pharmahands (Taizhou) Co., Ltd.!
Hotline:

+86-523-86200360

NEWS

The tax reduction of imported drugs has not been reduced, and the reform of pricing needs to be accelerated

Release:pharmahands Browse:248click

The tariff of the 28 categories of imported drugs dropped to zero, which is a good policy for people's livelihood. And how to make good policies play a "drug effect" as soon as possible depends on speeding up the reform of drug pricing mechanism.

In accordance with the relevant regulations of the State Council, since May 1st this year, China has reduced tariffs on 28 categories of imported drugs to zero, including the commonly used drugs for cancer treatment. But now more than a month ago, the media in the survey found that those who enjoy the import tariff new deal of the drug, the price of sale to the patient still still unmoved, so that the related family, rather lost.

It is indeed urgent that a good policy to benefit the people can not be turned into public benefits.

Anxious, at the same time, people will naturally wonder why the tariff on imported cars has just come out of the new deal, and the price of many cars will drop. And why is the price of imported anticancer drugs involved in saving lives great? Why is it so slow?

This is because China's automobile price is completely market adjusted, and the price of drugs must follow the government's pricing. The problem is that the price of drugs is not a department has the final say. It is necessary to negotiate with the manufacturers on the basis of consultations of the national Wei Jian Committee, the development and Reform Commission, the human society department and the medical insurance department. The execution process. For a new deal that began in May 1st, it is not easy to make corresponding adjustments in the short term. Moreover, the most original starting point for drug adjustment is tax rate adjustment. Besides tariffs, it involves VAT and requires more coordination or more.

At the same time, the sales of imported drugs in China are generally required by foreign enterprises to set up branches in China or search for agents. The price is also put on record in the country. It is not completely approved by the cost. Now because of the change of taxes and fees, it is necessary for the other party to adjust the price. The process of business and negotiation. In particular, some international pharmaceutical companies are dominant in some pharmaceutical fields and have strong voice in price.

In view of this situation, it is necessary for relevant departments to make appropriate adjustments to the management of drug prices.

First of all, we should rely on the market to make drug prices more in line with market rules. As a matter of fact, as early as May 2015, China issued a notice on promoting the reform of drug prices, and clearly pointed out that from June 1, 2015, in addition to narcotic drugs and psychotropic drugs, the other drugs were abolished by the government's pricing, and the drug purchase mechanism was perfected to play the role of medical insurance and control fees, and to strengthen the supervision of the drug market price and guide the supervision of the drug market. The price of drugs is more reasonable. However, so far, the market pricing mechanism of drugs has not really formed.

Secondly, for drug administration, we should minimize departments and implement unified management. For example, Japan's neighbouring countries are responsible for drug supervision by the Ministry of health and labour. The duties cover drug registration and approval, medical insurance management and drug pricing. This ensures the smooth flow of information in policy formulation and comprehensively takes into account the market supply and demand and financing level, and achieves good results. It is worth noting that our country has recently established the National Medical Security Bureau, which is expected to integrate the medical security functions of the past in many sectors, and believe that it can provide timely response to policy changes in drug management.

In the end, the patent of our country should be protected, but for some irreplaceable medical drugs, when negotiating the price with the related manufacturers, we may learn some foreign experience, set up the compulsory imitation clause when necessary, and increase the market's ability to adjust the price.

The tariff of the 28 categories of imported drugs dropped to zero, which is a good policy for people's livelihood. And how to make good policies play a "drug effect" as soon as possible depends on speeding up the reform of drug pricing mechanism.